Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Curie.Bio is a venture capital firm founded in 2022, headquartered in Cambridge/Boston, Massachusetts. The firm focuses on assisting founders in discovering and developing new medicines, particularly in the biotech and healthcare sectors. Curie.Bio operates as a hybrid model, combining seed venture capital with therapeutics acceleration and drug discovery copiloting.
As of early 2025, Curie.Bio manages approximately $1 billion in assets under management (AUM) across multiple funds. Their initial Seed Fund I was part of a $520 million raise in February 2023, followed by a $380 million Breakout Fund closed in June 2024, which is designed to support follow-on investments for their Seed portfolio through clinical trials. The firm has a selective investment strategy, with a sub-1% acceptance rate for new proposals.
Curie.Bio invests in early-stage therapeutics companies across various stages, from concept to clinical trials. Their investment strategy encompasses a wide range of modalities and therapeutic areas, with a specific focus on biotech and healthcare. The firm typically invests between $5 million and $15 million, with check sizes averaging around $7 million to $12 million per company.
The firm’s Seed Fund is aimed at advancing therapies through preclinical milestones, while the Breakout Fund provides further funding to support clinical trials. Curie.Bio emphasizes a unique approach that integrates investment with operational support, project management, and access to a network of experts, enabling founders to navigate the complexities of drug development effectively.
Curie.Bio has contributed to the development of over 100 drugs currently in clinical trials and has been involved in the approval of 44 medicines. Notable drugs developed with their support include:
In addition to these notable drugs, Curie.Bio has funded 26 startups as of January 2025, including Forward Therapeutics, which raised $50 million in a Series A round in November 2023, less than 18 months after an $8 million seed round. Other portfolio companies include Astoria Biologica, Decrypt Biomedicine, and Differentiated Therapeutics.
Zach Weinberg: Co-founder and CEO. Previously founded Flatiron Health, which was acquired by Roche in 2018. He brings extensive experience in healthcare and technology.
Alexis Borisy: Co-founder and Operating Chairman. Former partner at Third Rock Ventures, he is a prolific biotech founder and investor with a strong track record in the industry.
Christoph Lengauer, PhD, MBA: Co-founder and Chief Scientific Officer. He has a background at Third Rock Ventures and extensive expertise in drug development.
Tom Hotchkiss: Chief Infrastructure Officer, responsible for operational strategy and infrastructure development.
Ben Auspitz: Managing Partner of the Breakout Fund, focusing on follow-on investments for clinical-stage companies.
Chris De Savi, PhD: CSO Partner, contributing scientific expertise and guidance to portfolio companies.
Frank Stegmeier, PhD: CSO Partner, with a focus on drug discovery and development strategies.
Founders interested in pitching to Curie.Bio should submit their proposals through the designated contact page. It is recommended to include a detailed overview of the startup, the therapeutic area of focus, and the specific funding needs. Curie.Bio prefers well-structured decks that clearly outline the scientific rationale and development plan.
Response times may vary, but founders can expect to hear back within a few weeks. Warm introductions are encouraged, as they can facilitate the review process.
In June 2024, Curie.Bio closed a $380 million Breakout Fund aimed at supporting follow-on investments for their Seed portfolio through clinical trials. This fund is designed to enhance their capacity to back companies as they progress to clinical stages.
In November 2023, Forward Therapeutics, the first portfolio company, raised $50 million in a Series A round, demonstrating the firm's ability to help startups achieve rapid growth and funding milestones.
Curie.Bio has been featured in multiple industry publications, including STAT News and FierceBiotech, highlighting their innovative approach to venture capital and drug discovery support.
What stages does Curie.Bio invest in?
Curie.Bio invests in companies at various stages, including pre-seed, seed, Series A, Series B, and Series C. They focus on early-stage therapeutics companies.
What is the typical check size for investments?
The firm typically invests between $5 million and $15 million, with average check sizes ranging from $7 million to $12 million per company.
How can founders pitch to Curie.Bio?
Founders can submit their proposals through the Curie.Bio contact page. They encourage interested parties to share their proposals for potential funding or collaboration opportunities.
What makes Curie.Bio different from other venture capital firms?
Curie.Bio combines investment with drug discovery copiloting, providing operational support and access to a network of experts. This model allows founders to focus on scientific development rather than infrastructure.
What is the acceptance rate for proposals?
Curie.Bio has a highly selective investment strategy, with a sub-1% acceptance rate for new proposals, indicating a rigorous evaluation process for potential investments.
What types of companies does Curie.Bio prefer to invest in?
The firm focuses on biotech and healthcare companies that are developing therapeutics across various modalities and therapeutic areas. They seek scientific founders with differentiated therapeutic modalities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.